Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: Quantitative analysis of HER2 overexpression effects

被引:0
|
作者
Hendriks, BS
Opresko, LK
Wiley, HS
Lauffenburger, D [1 ]
机构
[1] MIT, Dept Chem Engn, Biol Engn Div, Cambridge, MA 02139 USA
[2] MIT, Canc Res Ctr, Cambridge, MA 02139 USA
[3] Pacific NW Natl Lab, Environm & Hlth Sci Div, Richland, WA 99352 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Elevated expression of human epidermal growth factor receptor 2 (HER2) is known to alter cell signaling and behavioral responses implicated in tumor progression. However, multiple diverse mechanisms may be involved in these overall effects, including signaling by HER2 itself, modulation of signaling by epidermal growth factor receptor (EGFR), and modification of trafficking dynamics for both EGFR and HER2. Because these processes are so tightly interrelated, the net effect of HER2 overexpression is difficult to reliably attribute to any single particular mechanism. To take an important first step toward dissecting the effects of HER2 overexpression on cell responses in terms of the various specific underlying mechanisms, we have developed and validated a quantitative model of the relevant trafficking processes. We then use our model for successful prediction of EGFR and HER2 level and location changes attributable to HER2 overexpression in 184A1 human mammary epithelial cells expressing a series of HER2 levels by retroviral infection. Model predictions are based on our independent experimental measurement of key trafficking parameters for both EGFR and HER2. In terms of trafficking processes, HER2 overexpression reduces the EGFR internalization rate constant and increases the fraction of EGFR recycled. Consequently, our model successfully predicts that HER2 increases the overall level of activated EGFR by both enhancing its recycling and reducing its internalization, but it increases activated EGFR localization at the cell surface almost solely by its reduction of internalization. Furthermore, the model also successfully predicts the effects of monoclonal antibody 2C4, which interferes with HER2/EGFR heterodimerization, on EGFR and HER2 levels and compartmental locations. We anticipate that this model should ultimately be useful in parsing the relative contributions of direct effects of HER2 via signaling vis-a-vis indirect effects of HER2 via modification of EGFR signaling.
引用
收藏
页码:1130 / 1137
页数:8
相关论文
共 50 条
  • [41] Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2)
    van de Vijver, MJ
    EUROPEAN JOURNAL OF CANCER, 2001, 37 : S11 - S17
  • [42] An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer
    Elshazly, Ahmed M.
    Gewirtz, David A.
    CANCER DRUG RESISTANCE, 2022, 5 (02) : 472 - 486
  • [43] A human epidermal growth factor receptor 3 (HER3)-binding nanoparticle targets and kills Herceptin®-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer
    Sims, J. D.
    Taguaim, M.
    Hanson, C.
    Cui, X.
    Medina-Kauwe, L. K.
    CANCER RESEARCH, 2013, 73
  • [44] Detecting Human Epidermal Growth Factor Receptor 2 (HER2) Amplification: Proof of Concept of an Alternative Approach
    Mudgal, Shikha
    Paul, Pranoy
    Ravi, Bina
    Agrawal, Shruti
    Kalra, Arnav
    Rao, Shalinee
    Chowdhury, Nilotpal
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [45] SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors
    Qu, D.
    Yan, A.
    Zhang, J. S.
    SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2017, 28 (02) : 111 - 132
  • [46] Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib
    Gilmer, Tona M.
    Cable, Louann
    Alligood, Krystal
    Rusnak, David
    Spehar, Glenn
    Gallagher, Kathleen T.
    Woldu, Ermias
    Carter, H. Luke
    Truesdale, Anne T.
    Shewchuk, Lisa
    Wood, Edgar R.
    CANCER RESEARCH, 2008, 68 (02) : 571 - 579
  • [47] Human epidermal growth factor receptor 2 (HER2) in gastric cancer (GC): results of the ToGA trial screening programme and recommendations for HER2 testing
    Chung, H.
    Bang, Y. J.
    Xu, J. M.
    Lordick, F.
    Sawaki, A.
    Lipatov, O.
    Lehle, M.
    Pickl, M.
    Rueschoff, J.
    Van Cutsem, E.
    EJC SUPPLEMENTS, 2009, 7 (02): : 364 - 364
  • [49] ASCO/CAP human epidermal growth factor receptor-2 (HER2) in situ hybridization (ISH) categories evaluated by quantitative HER2 protein diagnostic methodologies: A comparative analysis
    Buscaglia, B.
    Turner, B.
    Goda, H.
    Huang, W.
    Leitzel, K.
    Natori, T.
    Nakano, Y.
    Okada, H.
    Sperinde, J.
    Ali, S.
    Vasekar, M.
    D'Aguiar, M.
    McMahon, L.
    Henry, J.
    Lipton, A.
    Hicks, D.
    CANCER RESEARCH, 2019, 79 (04)
  • [50] Human epidermal growth factor receptor 2/3 (HER2/HER3) expression in higher-grade meningioma
    Mair, Maximilian
    Tomasich, Erwin
    Paiato, Christina
    Widhalm, Georg
    Eckert, Franziska
    Sahm, Felix
    Hainfellner, Johannes A.
    Berghoff, Anna Sophie
    Preusser, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)